title: Marrow transplantation following busulfan and cyclophosphamide for chronic myelogenous leukaemia in accelerated or blastic phase.
abstract: Between July 1984 and October 1987, 21 patients with chronic myelogenous leukaemia in an accelerated or blastic phase were treated with 16 mg/kg of busulfan and 120 mg/kg of cyclophosphamide followed by infusion of bone marrow from an HLA-identical sibling donor. The regimen was well tolerated. Except for one individual with severe marrow fibrosis all patients achieved a complete remission. Only one patient relapsed. Seven of 13 patients transplanted in an accelerated phase and five of eight transplanted in a blastic phase are alive without Philadelphia chromosomes between 8 and 48 months (median 29 months) following transplantation. The estimated probability of relapse-free 3-year survival is 55%. These results indicate that busulfan and cyclophosphamide combined with allogeneic marrow transplantation exert a potent anti-leukaemic effect in patients in the accelerated or blastic phase of CML.
authors.affiliation: Ohio State University, Bone Marrow Transplant Program, Columbus 43210.
authors.forename: E A
authors.initials: EA
authors.lastname: Copelan
authors.forename: M R
authors.initials: MR
authors.lastname: Grever
authors.forename: N
authors.initials: N
authors.lastname: Kapoor
authors.forename: P J
authors.initials: PJ
authors.lastname: Tutschka
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000627:therapeutic use*; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000209:etiology; D012074:Remission Induction; D012306:Risk
chemical_list: D003520:Cyclophosphamide; D002066:Busulfan